Sutro Biopharma, Inc. (STRO) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Sutro Biopharma, Inc. on December 1, 2025. The report details a material corporate action regarding the Company's capital structure, specifically the implementation of a reverse stock split.
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on the mechanics of a stock split.
Material Changes
- Reverse Stock Split: The Company implemented a 1-for-10 reverse stock split of its Common Stock, effective as of 12:01 am Eastern time on December 3, 2025.
- Share Count Reduction: Immediately prior to the split, there were approximately 85,193,912 shares outstanding. Post-split, the outstanding share count is approximately 8,519,392.
- Trading Adjustments: Common Stock began trading on a split-adjusted basis on December 3, 2025, under a new CUSIP number (869367201).
- Equity Plan Adjustments: Proportionate adjustments were made to the per-share exercise price and the number of shares issuable for all outstanding stock options and equity incentive plans.
- Fractional Shares: No fractional shares were issued; entitlements were rounded up to the nearest whole share.
Guidance, Outlook, and Risks
The filing does not provide updated financial guidance, management commentary on future operations, or specific risk factors beyond the standard disclosure that the description of the Amendment is qualified by the full text of the Amendment filed as Exhibit 3.1. The reverse stock split was authorized by stockholders on June 10, 2025, with a ratio range of 1-for-5 to 1-for-25, and the Board selected the 1-for-10 ratio on November 20, 2025.
Investor Verification Checklist
- Verify the new CUSIP number (869367201) for trading purposes effective December 3, 2025.
- Confirm the adjusted number of shares held in brokerage accounts following the 1-for-10 consolidation.
- Review the adjusted exercise prices and share quantities for any outstanding stock options or equity awards.
- Check for any rounding adjustments if the pre-split shareholding resulted in a fractional share entitlement.